Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8849404rdf:typepubmed:Citationlld:pubmed
pubmed-article:8849404lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:8849404lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8849404lifeskim:mentionsumls-concept:C0021853lld:lifeskim
pubmed-article:8849404lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:8849404lifeskim:mentionsumls-concept:C0042866lld:lifeskim
pubmed-article:8849404lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8849404lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:8849404lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:8849404pubmed:issue5lld:pubmed
pubmed-article:8849404pubmed:dateCreated1996-12-3lld:pubmed
pubmed-article:8849404pubmed:abstractTextThe effects on renal and intestinal calbindin-D of vitamin D3 metabolites and synthetic 20-epi-vitamin D3 analogs with different calcemic actions were examined in Wistar rats. The compounds were administered intraperitoneally once daily for 5 days. The dosages of the metabolites were 1,25-(OH)2D3 0.01, 0.05, 0.1, and 0.4 microg/kg x d, 24,25-(OH)2D3 0.1, 1 and 10 microg/kg x d, and 25-(OH)D3 10 and 400 microg/kg x d. The dosage of the synthetic analogs were MC903 0. 1, 10, and 100 microg/kg x d, EB1213 0.1 and 10 microg/kg x d, KH1060 0.1 and 0.4 microg/kg x d, and GS1725 0.01 and 0.1 microg/kg x d. Two control groups had either vehicle alone or no treatment. N = 8 in each group. 1,25-(OH)2D3 increased renal and intestinal calbindin-D levels, induced hypercalcemia, and suppressed plasma PTH and magnesium concentrations. 24,25-(OH)2D3 increased intestinal calbindin-D9k and plasma calcium, but had no effect on renal calbindin-D28k, plasma PTH, and magnesium. The dosage of 24, 25-(OH)2D3 that was required to increase plasma calcium was larger than the dosage required to increase intestinal calbindin-D9k. 25-(OH)D3 did not change the calcium metabolic parameters. MC903, a low calcemic analog with a relative high affinity for the vitamin D receptor and a short half-life, increased renal calbindin-D28k without increasing ionized calcium or intestinal calbindin-D9k. EB1213, an analog with a reduced calcemic action and short half-life, increased renal calbindin-D28k and ionized calcium without increasing intestinal calbindin-D9k. The effect of the high calcemic vitamin D analogs KH1060 and GS1725 on calbindin-D was directly related to their calcemic activity. In conclusion, these results demonstrate that 24,25-(OH)2D3 increases intestinal calbindin-D9k, but has no effect on renal calbindin-D28k, that low calcemic analogs may increase renal calbindin-D28k without increasing intestinal calbindin-D9k, and that the effect of high calcemic analogs on calbindin-D is directly related to their calcemic activity.lld:pubmed
pubmed-article:8849404pubmed:languageenglld:pubmed
pubmed-article:8849404pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8849404pubmed:citationSubsetIMlld:pubmed
pubmed-article:8849404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8849404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8849404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8849404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8849404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8849404pubmed:statusMEDLINElld:pubmed
pubmed-article:8849404pubmed:monthNovlld:pubmed
pubmed-article:8849404pubmed:issn0171-967Xlld:pubmed
pubmed-article:8849404pubmed:authorpubmed-author:OlgaardKKlld:pubmed
pubmed-article:8849404pubmed:authorpubmed-author:StaunMMlld:pubmed
pubmed-article:8849404pubmed:authorpubmed-author:LewisNNlld:pubmed
pubmed-article:8849404pubmed:authorpubmed-author:NielsenP KPKlld:pubmed
pubmed-article:8849404pubmed:authorpubmed-author:HemmingsenCClld:pubmed
pubmed-article:8849404pubmed:issnTypePrintlld:pubmed
pubmed-article:8849404pubmed:volume59lld:pubmed
pubmed-article:8849404pubmed:ownerNLMlld:pubmed
pubmed-article:8849404pubmed:authorsCompleteYlld:pubmed
pubmed-article:8849404pubmed:pagination371-6lld:pubmed
pubmed-article:8849404pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:meshHeadingpubmed-meshheading:8849404-...lld:pubmed
pubmed-article:8849404pubmed:year1996lld:pubmed
pubmed-article:8849404pubmed:articleTitleEffect of vitamin D metabolites and analogs on renal and intestinal calbindin-D in the rat.lld:pubmed
pubmed-article:8849404pubmed:affiliationDepartment of Nephrology P-2131, Rigshospitalet, 9, Blegdamsvej, University of Copenhagen, DK-2100 Copenhagen, Denmark.lld:pubmed
pubmed-article:8849404pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8849404pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed